Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of Lais Graminacee sublingual drops in grass pollen allergic rhinoconjunctivitis
2018-004472-35Phase 2Completed
- Sponsor
- Lofarma S.p.A.
- Start
- Dec 2018
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lais Graminacee in allergic rhinoconjunctivitis (ARC), sponsored by Lofarma S.p.A. Primary endpoint: Primary safety and clinical tolerability. Started Dec 2018; status: completed.
02
Drugs
Lais Graminacee
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2018-004472-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004472-35.